Vaxcyte reports positive OPUS-1 topline data for VAX-31, outlines BLA path to first half of 2028
The company says VAX-31 met all primary endpoints in its pivotal adult Phase 3 trial, with pro forma cash of about $3.4 billion after October financings.
SEC filing